INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pancreas Cancer Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Neoplasms Neoplasms by Site Pancreatic Adenocarcinoma Pancreatic Diseases Pancreatic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hop Claude Huriez Chu Lille

Lille, 59037, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients > 18 years of age at diagnosis
Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016
Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma
Tissue blocks (FFPE) available (tumour/healthy tissue)
Affiliated to a social security scheme

Exclusion criteria

Absence of Primary Cancer Tissue Blocks (PCTBs)
Paraffin block fixed in Bouin or AFA
Patient Refusal
Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).
Patient died due to post-surgical complications (death within 30 days post-surgery).
Surgical resection of macroscopic R2 type.

Treatment and study plan

Primary outcomes

Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.

Time frame: at 2 years

Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.

Secondary outcomes

Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.

Time frame: at 2 years

Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Registry information

Acronym: CaPaLong

Important dates

Study start: 2021
Primary completion: 2025
Study completion: 2025
First posted: Jun 18, 2020
Registry last updated: Mar 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed